FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

D.C. 20549 OMB APPROVAL	D C 20E40	
	D.C. 20549	OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  LINK MAX					2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ ALXN ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
												:	X Directo	r		10% Ow	ner		
(Last)	(Fi	irst)	(Middle)			72 11 1	J							Officer below)	(give title		Other (s below)	pecify	
C/O ALEXION PHARMACEUTICALS				3. Date of Earliest Transaction (Month/Day/Year) 05/07/2013															
352 KNC	OTTER DR	IVE			4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	RE C	r	06410						·				Line	•	led by One	Repoi	rting Persor	.	
CHESHI	RE C	1	00410											Form fi Persor		e than	One Repor	ting	
(City)	(S	tate)	(Zip)																
		Tak	ole I - Non-	-Deriva	ative	e Se	curities	Ac	quired, [	Disp	osed of	f, or Ben	eficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution D		Date,	Code (Ir	Transaction Disposed Of (D) (Instr. 3, 2) Code (Instr. 5)					es Formally (D) (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Co	4. Transaction Code (Instr		5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Option to Purchase Common Stock	\$96.35	05/07/2013			A		3,425 <sup>(1)</sup>		08/07/201	3 (	05/07/2023	Common Stock, par value \$.0001 per share	3,425	\$0	3,425		D		

#### **Explanation of Responses:**

1. These options will vest in four quarterly installments during the one year period commencing on May 7, 2013 and ending on May 7, 2014.

#### Remarks:

/s/ Max Link

05/07/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.